Project Grant R43AI197624
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48823, USA
Similar Awards
- Federal Project Grant Award Summary Award Details: Abvacc, Inc. received a $638,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was issued on August 22, 2025, with a completion date of July 31, 2030, and performance will be conducted in Rockville, Maryland. Products and Services: The grant funds development of an immunotherapeutic antibody cocktail for treating...
- Federal Grant Award Summary Wayne State University's Sponsored Project Administration Division received a $1.34 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 13, 2026, with a completion date of January 31, 2031. The grant funds research to develop and optimize phage-antibiotic combination (PAC) therapies targeting multidrug-resistant Staphylococcus aureus...
- Federal Project Grant Award Summary Michigan State University received a $413,092 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 8, 2026, with completion scheduled for May 31, 2028. The award supports fundamental research to elucidate the molecular mechanisms of CBRA transceptor signaling in Pseudomonas aeruginosa, a leading nosocomial pathogen. The research...
- Summary of Federal Project Grant Award Vishenary, LLC received a $308,669 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 23, 2025, with a completion date of March 31, 2027. The grant funds the development of a novel vaccine candidate designed to provide broad protection against nontypeable Haemophilus influenzae (NTHI) infection following influenza A virus...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Washington University a Project Grant of $664,076 under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026, through March 31, 2031. This five-year award funds research to elucidate the molecular mechanisms by which Staphylococcus aureus alpha-toxin (HLA) impairs antigen-specific T cell responses and adaptive immunity. The research integrates human...
- Federal Grant Award Summary Biotherapeutics, Inc. received a $628,726 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 13, 2025, with completion targeted for January 31, 2026. The grant funds Phase I Small Business Innovation Research (SBIR) activities to develop a novel, oral, host-targeted therapeutic candidate designed to treat patients with concomitant...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,609,410 Project Grant to the University of California, San Diego, effective February 20, 2026, through January 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates mechanisms of vaccine interference induced by pre-existing anti-Staphylococcus aureus (SA) antibodies and B cells, addressing a critical gap in vaccine...
- Federal Project Grant Award Summary Sunflower Therapeutics PBC received a $306,347 Fast-Track Small Business Innovation Research (SBIR) Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), dated August 21, 2025, with a completion target of July 31, 2026. The award supports development of an automated, continuous cell disruption system integrated with the company's existing Daisy Petal...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $800,557 (Award Date: February 19, 2026; Ultimate Completion Date: January 31, 2031) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct basic immunological research on Staphylococcus aureus pathogenesis. The project seeks to identify mechanisms by which S. aureus manipulates inflammasome activities—key components of...
- Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 11, 2025, through August 31, 2026. The company is developing a microneedle-based messenger RNA (mRNA) flu vaccine candidate designed for transcutaneous (intradermal) immunization. The project leverages Via Therapeutics' proprietary thin-film...